In December, 120 senior figures from industry and academia will be uniting at the foremost gene editing drug development meeting, the 5th Genome Editing Therapeutics Summit (formerly known as CRISPR 2.0).
Across three days, industry and academic leaders will share their latest data for attendees to improve the robustness of nonclinical and safety packages (including off-target and genotoxicity assessments), unlock efficient, cell- and tissue- specific delivery (particularly in vivo); and translate new editing technologies into clinical programs.
Here’s a snapshot of the 30+ speakers to expect in the room:
- Jeffrey Cehelsky, VP, Development Operations, Intellia Therapeutics
- Sheryl Bowley, Director, HSC Therapies, Editas Medicine
- Luca Biasco, VP, Translational Sciences, Nvelop Therapeutics
- Priya Chockalingam, VP, Head of Clinical Bioanalytics & Translational, Beam Therapeutics
- Sam Sternberg, Assistant Professor, Columbia University
- Vivian Choi, Head of Liver, Metabolic, Lung, Eye & Ear Disease Unit, Prime Medicine
Ready to join them? Sign up before Friday 18 October and save up to $600 on your pass.